Literature DB >> 17244626

Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families.

Minji Kim1, Louis B Hersh, Malcolm A Leissring, Martin Ingelsson, Toshifumi Matsui, Wesley Farris, Alice Lu, Bradley T Hyman, Dennis J Selkoe, Lars Bertram, Rudolph E Tanzi.   

Abstract

Insulin-degrading enzyme (IDE) is a zinc metalloprotease that degrades the amyloid beta-peptide, the key component of Alzheimer disease (AD)-associated senile plaques. We have previously reported evidence for genetic linkage and association of AD on chromosome 10q23-24 in the region harboring the IDE gene. Here we have presented the first functional assessment of IDE in AD families showing the strongest evidence of the genetic linkage. We have examined the catalytic activity and expression of IDE in lymphoblast samples from 12 affected and unaffected members of three chromosome 10-linked AD pedigrees in the National Institute of Mental Health AD Genetics Initiative family sample. We have shown that the catalytic activity of cytosolic IDE to degrade insulin is reduced in affected versus unaffected subjects of these families. Further, we have shown the decrease in activity is not due to reduced IDE expression, suggesting the possible defects in IDE function in these AD families. In attempts to find potential mutations in the IDE gene in these families, we have found no coding region substitutions or alterations in splicing of the canonical exons and exon 15b of IDE. We have also found that total IDE mRNA levels are not significantly different in sporadic AD versus age-matched control brains. Collectively, our data suggest that the genetic linkage of AD in this set of chromosome 10-linked AD families may be the result of systemic defects in IDE activity in the absence of altered IDE expression, further supporting a role for IDE in AD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17244626     DOI: 10.1074/jbc.M609168200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  CD44 contributes to hyaluronan-mediated insulin resistance in skeletal muscle of high-fat-fed C57BL/6 mice.

Authors:  Annie Hasib; Chandani K Hennayake; Deanna P Bracy; Aimée R Bugler-Lamb; Louise Lantier; Faisel Khan; Michael L J Ashford; Rory J McCrimmon; David H Wasserman; Li Kang
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-09-24       Impact factor: 4.310

Review 2.  Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.

Authors:  Wei-Jen Tang
Journal:  Trends Endocrinol Metab       Date:  2015-12-02       Impact factor: 12.015

3.  Yeast Ste23p shares functional similarities with mammalian insulin-degrading enzymes.

Authors:  Benjamin J Alper; Jarrad W Rowse; Walter K Schmidt
Journal:  Yeast       Date:  2009-11       Impact factor: 3.239

4.  Comparative protein interactomics of neuroglobin and myoglobin.

Authors:  Bryan A Haines; Darcy A Davis; Artem Zykovich; Botao Peng; Rammohan Rao; Sean D Mooney; Kunlin Jin; David A Greenberg
Journal:  J Neurochem       Date:  2012-08-14       Impact factor: 5.372

5.  Cell-permeable, small-molecule activators of the insulin-degrading enzyme.

Authors:  Sayali S Kukday; Surya P Manandhar; Marissa C Ludley; Mary E Burriss; Benjamin J Alper; Walter K Schmidt
Journal:  J Biomol Screen       Date:  2012-06-26

Review 6.  Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease.

Authors:  Khalid Iqbal; M Omar Chohan; Inge Grundke-Iqbal
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

7.  A monomeric variant of insulin degrading enzyme (IDE) loses its regulatory properties.

Authors:  Eun Suk Song; David W Rodgers; Louis B Hersh
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

8.  Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.

Authors:  Mallory Gough; Catherine Parr-Sturgess; Edward Parkin
Journal:  Biochem Res Int       Date:  2010-09-30

9.  Type 2 diabetes and Alzheimer's disease: from common pathologies to potential new therapeutics.

Authors:  Daniel E Levy
Journal:  J Diabetes Sci Technol       Date:  2007-07

10.  Involvement of insulin-degrading enzyme in the clearance of beta-amyloid at the blood-CSF barrier: Consequences of lead exposure.

Authors:  Mamta Behl; Yanshu Zhang; Wei Zheng
Journal:  Cerebrospinal Fluid Res       Date:  2009-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.